-transparent.png){kind=logo}
The capacity for sparteine (SP) metabolism was determined in 48 Caucasian subjects by measuring amounts of drug and dehydrogenated metabolites in urine after an oral dose of SP sulfate. Three phenotypes were recognized and were assumed to represent individuals homozygous for poor SP oxidation (group III) and those heterozygous (group II) and homozygous (group I) for extensive SP oxidation. Separation of groups I and II, although incomplete, was improved by alterations in the published analytic procedure. The pattern of deviations from the normal distribution was similar for both dehydrosparteine metabolites. This supports the hypothesis of a common intermediate, the formation of which is monogenically controlled. Correlation analysis of the two metabolites indicates the possibility of further metabolism of 5-dehydrosparteine.
A Vinks, and
T Inaba, and
S V Otton, and
W Kalow
November 1984,
Clinical pharmacology and therapeutics,
A Vinks, and
T Inaba, and
S V Otton, and
W Kalow
January 1996,
Drug metabolism and drug interactions,
A Vinks, and
T Inaba, and
S V Otton, and
W Kalow
April 1980,
Clinical pharmacology and therapeutics,
A Vinks, and
T Inaba, and
S V Otton, and
W Kalow
May 1986,
Xenobiotica; the fate of foreign compounds in biological systems,
A Vinks, and
T Inaba, and
S V Otton, and
W Kalow
June 1984,
Clinical pharmacology and therapeutics,
A Vinks, and
T Inaba, and
S V Otton, and
W Kalow
December 1989,
Journal of neurology,
A Vinks, and
T Inaba, and
S V Otton, and
W Kalow
September 2004,
Canadian respiratory journal,
A Vinks, and
T Inaba, and
S V Otton, and
W Kalow
January 1978,
Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
A Vinks, and
T Inaba, and
S V Otton, and
W Kalow
August 1973,
Journal of animal science,
A Vinks, and
T Inaba, and
S V Otton, and
W Kalow
January 1977,
Vox sanguinis,
